Current and historical daily PE Ratio for SELLAS Life Sciences Group Inc (
FRA:RXK3
) from 2008 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. SELLAS Life Sciences Group stock (FRA:RXK3) PE ratio as of Jun 19 2024 is 0.
More Details
SELLAS Life Sciences Group Inc (FRA:RXK3) PE Ratio (TTM) Chart
SELLAS Life Sciences Group Inc (FRA:RXK3) PE Ratio (TTM) Historical Data
View and export this data going back to 2008. Start your Free Trial
Total 1288
- 1
- 2
- 3
- 4
- 5
- 6
- 15
SELLAS Life Sciences Group PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-19 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-03-28 | At Loss |
2024-06-03 | At Loss | 2024-03-27 | At Loss |
2024-05-31 | At Loss | 2024-03-26 | At Loss |
2024-05-30 | At Loss | 2024-03-25 | At Loss |
2024-05-29 | At Loss | 2024-03-22 | At Loss |
2024-05-28 | At Loss | 2024-03-21 | At Loss |
2024-05-27 | At Loss | 2024-03-20 | At Loss |
2024-05-24 | At Loss | 2024-03-19 | At Loss |
2024-05-23 | At Loss | 2024-03-18 | At Loss |
2024-05-22 | At Loss | 2024-03-15 | At Loss |
2024-05-21 | At Loss | 2024-03-14 | At Loss |
2024-05-20 | At Loss | 2024-03-13 | At Loss |
2024-05-17 | At Loss | 2024-03-12 | At Loss |
2024-05-16 | At Loss | 2024-03-11 | At Loss |
2024-05-15 | At Loss | 2024-03-08 | At Loss |
2024-05-14 | At Loss | 2024-03-07 | At Loss |
2024-05-13 | At Loss | 2024-03-06 | At Loss |
2024-05-10 | At Loss | 2024-03-05 | At Loss |
2024-05-09 | At Loss | 2024-03-04 | At Loss |
2024-05-08 | At Loss | 2024-03-01 | At Loss |
2024-05-07 | At Loss | 2024-02-29 | At Loss |
2024-05-06 | At Loss | 2024-02-28 | At Loss |
2024-05-03 | At Loss | 2024-02-27 | At Loss |
2024-05-02 | At Loss | 2024-02-26 | At Loss |
2024-04-30 | At Loss | 2024-02-23 | At Loss |
2024-04-29 | At Loss | 2024-02-22 | At Loss |
2024-04-26 | At Loss | 2024-02-21 | At Loss |
2024-04-25 | At Loss | 2024-02-20 | At Loss |
2024-04-24 | At Loss | 2024-02-19 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
SELLAS Life Sciences Group Inc (FRA:RXK3) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
SELLAS Life Sciences Group Inc
NAICS : 325412
SIC : 2834
ISIN : US81642T1007
Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.